Blennow M, Hedenskog S, Granström M
Department of Pediatrics, Sachs' Childrens' Hospital, Stockholm, Sweden.
Eur J Clin Microbiol Infect Dis. 1988 Jun;7(3):381-3. doi: 10.1007/BF01962341.
Two acellular pertussis vaccines, a mono-component toxoid of pertussis toxin and a two-component vaccine containing both the toxoid and filamentous haemagglutinin, were used for primary immunization of infants 5 1/2 to 10 months of age in two clinical trials in Sweden. Over a follow-up period of 12 to 17 months, 37 children were exposed to pertussis in the household or a daycare centre. Only one child developed mild, culture-confirmed pertussis as opposed to the expected number of 30 to 33 cases based on an assumed attack rate of 80-90% in non-immunized children. These preliminary findings indicate that, given as primary immunization to infants, the vaccines provide protection against pertussis.
在瑞典的两项临床试验中，两种无细胞百日咳疫苗，一种是百日咳毒素单组分类毒素，另一种是包含类毒素和丝状血凝素的双组分疫苗，用于对5个半月至10个月大的婴儿进行初次免疫。在12至17个月的随访期内，37名儿童在家中或日托中心接触了百日咳。只有一名儿童出现了轻度的、经培养确诊的百日咳，而根据未免疫儿童80%-90%的假定发病率，预期病例数为30至33例。这些初步研究结果表明，作为婴儿的初次免疫疫苗，这些疫苗可提供针对百日咳的保护。
